Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference25 articles.
1. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes;List;Cancer Control,2008
2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997
3. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group;Bennett;Ann Intern Med,1985
4. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B;Silverman;J Clin Oncol,2002
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Inflamma-miRs Profile in Myelodysplastic Syndrome Patients;International Journal of Molecular Sciences;2024-06-20
2. Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide;eJHaem;2023-08-25
3. Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients;Antioxidants;2022-01-09
4. Epigenetic deregulation in myeloid malignancies;Blood;2021-06-22
5. Current Therapy of the Patients with MDS: Walking towards Personalized Therapy;Journal of Clinical Medicine;2021-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3